Harvey Partners’s Rentokil RTO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.7M Buy
975,500
+89,331
+10% +$2.81M 2.44% 19
2025
Q4
$26.1M Buy
886,169
+1,169
+0.1% +$32.5K 2.31% 21
2025
Q3
$22.3M Sell
885,000
-335,000
-27% -$8.16M 1.99% 24
2025
Q2
$29.3M Sell
1,220,000
-422,000
-26% -$9.78M 2.87% 13
2025
Q1
$37.6M Buy
1,642,000
+14,500
+0.9% +$350K 4.39% 4
2024
Q4
$41.2M Buy
1,627,500
+197,500
+14% +$5M 4.58% 5
2024
Q3
$35.6M Buy
1,430,000
+465,500
+48% +$13.8M 4.06% 6
2024
Q2
$28.6M Buy
964,500
+114,500
+13% +$3.18M 3.44% 11
2024
Q1
$25.6M Buy
850,000
+29,877
+4% +$829K 2.71% 16
2023
Q4
$23.5M Buy
820,123
+174,623
+27% +$5.13M 2.67% 17
2023
Q3
$23.9M Buy
645,500
+53,000
+9% +$2.02M 3.03% 12
2023
Q2
$23.1M Buy
592,500
+2,000
+0.3% +$78.4K 2.83% 14
2023
Q1
$21.6M Buy
590,500
+57,204
+11% +$1.81M 2.67% 18
2022
Q4
$16.4M Buy
+533,296
New +$16.6M 2.09% 24

Other funds holding RTO

Harvey Partners's RTO Position: Q1 2026 in Review

Harvey Partners increased its Rentokil (RTO) stake by 10% in Q1 2026, buying an estimated $2.81M and bringing the position to 975,500 shares worth $30.7M. The position accounts for 2.44% of the portfolio, ranked #19.

Harvey Partners first reported a position in RTO in Q4 2022 and has held it in 14 quarters since. The position peaked at $41.2M in Q4 2024. 282 funds tracked by Wall St. Rank hold RTO as of Q1 2026.

  • Harvey Partners held 975,500 shares of Rentokil worth $30.7M as of Q1 2026.
  • Harvey Partners bought 89,331 Rentokil shares in Q1 2026, an estimated $2.81M.
  • Rentokil made up 2.44% of Harvey Partners's portfolio in Q1 2026, its #19 holding.
  • Harvey Partners first reported a position in Rentokil in Q4 2022 and has held it in 14 quarters since.
  • Harvey Partners's Rentokil position peaked at $41.2M in Q4 2024.
  • 282 funds tracked by Wall St. Rank held Rentokil as of Q1 2026.

Based on Harvey Partners's 13F filing for Q1 2026, filed 15 May 2026.